JP2014534962A5 - - Google Patents

Download PDF

Info

Publication number
JP2014534962A5
JP2014534962A5 JP2014535865A JP2014535865A JP2014534962A5 JP 2014534962 A5 JP2014534962 A5 JP 2014534962A5 JP 2014535865 A JP2014535865 A JP 2014535865A JP 2014535865 A JP2014535865 A JP 2014535865A JP 2014534962 A5 JP2014534962 A5 JP 2014534962A5
Authority
JP
Japan
Prior art keywords
composition
naglu
rhnaglu
protein
rhnaglu protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014535865A
Other languages
English (en)
Japanese (ja)
Other versions
JP6329483B2 (ja
JP2014534962A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/059708 external-priority patent/WO2013055888A2/en
Publication of JP2014534962A publication Critical patent/JP2014534962A/ja
Publication of JP2014534962A5 publication Critical patent/JP2014534962A5/ja
Application granted granted Critical
Publication of JP6329483B2 publication Critical patent/JP6329483B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014535865A 2011-10-12 2012-10-11 組換えヒトｎａｇｌｕタンパク質およびその利用 Expired - Fee Related JP6329483B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161546248P 2011-10-12 2011-10-12
US61/546,248 2011-10-12
PCT/US2012/059708 WO2013055888A2 (en) 2011-10-12 2012-10-11 Recombinant human naglu protein and uses thereof

Publications (3)

Publication Number Publication Date
JP2014534962A JP2014534962A (ja) 2014-12-25
JP2014534962A5 true JP2014534962A5 (cg-RX-API-DMAC7.html) 2015-11-26
JP6329483B2 JP6329483B2 (ja) 2018-05-23

Family

ID=48082738

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014535865A Expired - Fee Related JP6329483B2 (ja) 2011-10-12 2012-10-11 組換えヒトｎａｇｌｕタンパク質およびその利用

Country Status (18)

Country Link
US (3) US9579366B2 (cg-RX-API-DMAC7.html)
EP (1) EP2766477B1 (cg-RX-API-DMAC7.html)
JP (1) JP6329483B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140108519A (cg-RX-API-DMAC7.html)
CN (1) CN103958676A (cg-RX-API-DMAC7.html)
AU (1) AU2012322811A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014008873A2 (cg-RX-API-DMAC7.html)
CA (1) CA2852027A1 (cg-RX-API-DMAC7.html)
CL (1) CL2014000927A1 (cg-RX-API-DMAC7.html)
CO (1) CO7010783A2 (cg-RX-API-DMAC7.html)
HK (1) HK1200489A1 (cg-RX-API-DMAC7.html)
IL (1) IL232073A0 (cg-RX-API-DMAC7.html)
IN (1) IN2014MN00740A (cg-RX-API-DMAC7.html)
MX (1) MX2014004359A (cg-RX-API-DMAC7.html)
RU (1) RU2014117291A (cg-RX-API-DMAC7.html)
SG (2) SG11201401457SA (cg-RX-API-DMAC7.html)
TW (1) TW201321515A (cg-RX-API-DMAC7.html)
WO (1) WO2013055888A2 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8759297B2 (en) 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
WO2009018122A2 (en) 2007-07-27 2009-02-05 Armagen Technologies, Inc. Methods and compositions for increasing alpha-iduronidase activity in the cns
EP2485761B1 (en) 2009-10-09 2019-02-27 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
US8663631B2 (en) 2010-09-09 2014-03-04 Synageva Biopharma Corporation Methods for treating lysosomal acid lipase deficiency in patients
KR20140006037A (ko) 2011-02-15 2014-01-15 시나게바 바이오파르마, 코포레이션 리소좀의 산 리파제 결핍을 치료하는 방법들
RU2014117291A (ru) * 2011-10-12 2015-11-20 Синаджева Биофарма Корп. Рекомбинантный человеческий белок naglu и его применение
CA2857647C (en) 2011-12-02 2022-04-19 Armagen Technologies, Inc. Methods and compositions for increasing arylsulfatase a activity in the cns
EP3622821A1 (en) * 2013-05-15 2020-03-18 Regents of the University of Minnesota Adeno-associated virus mediated gene transfer to the central nervous system
TW202332774A (zh) * 2013-10-23 2023-08-16 美商健臻公司 重組醣蛋白及其用途
SG11201609314XA (en) * 2014-05-14 2016-12-29 Esteve Labor Dr Adenoassociated virus vectors for the treatment of lysosomal storage disorders
EP3160494B1 (en) * 2014-06-25 2019-11-20 Shire Human Genetic Therapies, Inc. Generation of mannose-6-phosphate containing recombinant alpha-n-acetyl glucosaminidase
AU2015301809A1 (en) * 2014-08-11 2017-02-02 Shire Human Genetic Therapies, Inc. Mannose-6-phosphate bearing peptides fused to lysosomal enzymes
AU2015323966A1 (en) 2014-09-29 2017-03-16 Alexion Pharmaceuticals, Inc. Methods of treating mucopolysaccharidosis IIIB (MPSIIIB)
CN104524662B (zh) * 2014-12-31 2017-02-22 迈得医疗工业设备股份有限公司 一种医用针座组装的上料机构
US10538589B2 (en) * 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
US20190083583A1 (en) * 2016-01-29 2019-03-21 Alexion Pharmaceuticals, Inc. Enzyme replacement therapy in mucopolysaccharidosis iiib patients
MA44874A (fr) 2016-04-15 2019-03-13 Univ Pennsylvania Thérapie génique pour traiter la mucopolysaccharidose de type ii
US10633705B2 (en) 2016-10-14 2020-04-28 Alexion Pharmaceuticals, Inc. N-acetyl-alpha-D-glucosaminidase deficiency compositions and methods
IL273427B2 (en) 2017-09-22 2025-04-01 Univ Pennsylvania Gene therapy for the treatment of mucocutaneous polycythemia vera type II
US20200277584A1 (en) 2017-10-02 2020-09-03 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
CA3169548A1 (en) * 2020-03-23 2021-09-30 Haiyan Fu Aav-naglu vectors for treatment of mucopolysaccharidosis iiib
CN111718947B (zh) * 2020-06-18 2022-08-23 舒泰神（北京）生物制药股份有限公司 用于治疗ⅲa或ⅲb型粘多糖贮积症的腺相关病毒载体及用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6825396B2 (en) 1996-06-12 2004-11-30 Board Of Trustees Operating Michigan State University Methods for tissue specific synthesis of protein in eggs of transgenic hens
US5897998A (en) 1997-08-04 1999-04-27 The University Of Georgia Research Foundation, Inc. Method for manipulating avian eggs
ES2357495T3 (es) 1997-10-16 2011-04-27 University Of Georgia Research Foundation, Inc. Aves transgénicas y producción de proteína.
US20040019923A1 (en) 1997-10-16 2004-01-29 Ivarie Robert D. Exogenous proteins expressed in avians and their eggs
US7511120B2 (en) 1997-10-16 2009-03-31 Synageva Biopharma Corp. Glycosylated G-CSF obtained from a transgenic chicken
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
US6537785B1 (en) * 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US6875588B2 (en) 2001-11-30 2005-04-05 Avigenics, Inc. Ovomucoid promoter and methods of use
US7294507B2 (en) 2001-11-30 2007-11-13 Avigenics, Inc. Ovomucoid promoters and methods of use
US6679165B2 (en) 2002-05-22 2004-01-20 Shiny Shih Window adapted to a dater
US20050142141A1 (en) * 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
ES2371913T3 (es) 2003-01-22 2012-01-11 Duke University Constructos mejorados para expresar polipéptidos lisosomales.
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US20050090001A1 (en) 2003-10-07 2005-04-28 Parker Stephen H. Cell lines and methods for producing proteins
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
WO2005107491A2 (en) * 2004-05-05 2005-11-17 Northeastern University Multi-lectin affinity chromatography and uses thereof
CA2641070C (en) 2006-02-06 2017-01-03 Ramot At Tel-Aviv University Ltd. Enzyme replacement therapy for treating lysosomal storage diseases
CN101410408A (zh) 2006-04-04 2009-04-15 希尔制药爱尔兰有限责任公司 用于浓缩多肽的方法
EP2126071A4 (en) 2007-01-26 2010-12-08 Synageva Biopharma Corp TRANSGENEXPRESSION IN BIRDS
US8431770B2 (en) * 2008-01-07 2013-04-30 Synageva Biopharma Corp. Method of producing sialytransferase-modified proteins
WO2009131698A2 (en) * 2008-04-23 2009-10-29 Iowa State University Research Foundation, Inc. PHOSPHORYLATED RECOMBINANT N-ACETYL-alpha-D- GLUCOSAMINIDASE (NaGlu) AND USES THEREOF
JP5837486B2 (ja) * 2009-07-03 2015-12-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル カチオン非依存性マンノース６−リン酸受容体を標的とする化合物
JP6063380B2 (ja) * 2010-06-25 2017-01-18 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド サンフィリポ症候群ｂ型の処置
WO2011163648A1 (en) * 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
EP2975134A3 (en) 2010-07-22 2016-02-24 Shire Human Genetic Therapies, Inc. Crystal structure of human alpha-n-acetylglucosaminidase
US8663631B2 (en) 2010-09-09 2014-03-04 Synageva Biopharma Corporation Methods for treating lysosomal acid lipase deficiency in patients
RU2014117291A (ru) * 2011-10-12 2015-11-20 Синаджева Биофарма Корп. Рекомбинантный человеческий белок naglu и его применение

Similar Documents

Publication Publication Date Title
JP2014534962A5 (cg-RX-API-DMAC7.html)
RU2014117291A (ru) Рекомбинантный человеческий белок naglu и его применение
ES2690147T3 (es) Apelina pegilada y usos de la misma
ES2281341T3 (es) Lectina humana recombinante que se une a manano.
ES2635990T3 (es) Nanopartículas de quitosano derivado dualmente y los métodos para fabricar y usar las mismas para la transferencia génica in vivo
ES2597954T3 (es) Conjugados de proteína de la coagulación sanguínea
US11697678B2 (en) Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof
US11241486B2 (en) Treatment of Middle East respiratory syndrome coronavirus
WO2009150284A9 (es) Conjugados de apo-a para la administración de compuestos biológicamente activos
US20210386868A1 (en) Extracellular vesicles for replacement of urea cycle proteins & nucleic acids
JP2017529326A5 (cg-RX-API-DMAC7.html)
KR20170029576A (ko) 골형성단백질의 치료적 용도
CA3103847A1 (en) Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases
US20200164049A1 (en) Treatment of human metapneumovirus
HRP20211197T1 (hr) Rekombinantni glikoproteini i njihova uporaba
US12138296B2 (en) Formulations for bovine granulocyte colony stimulating factor and variants thereof
ES2296529B1 (es) Composicion farmaceutica con promotores de absorcion.
US20230203507A1 (en) Modified mini-nucleosome core proteins and use in nucleic acid delivery
US20220233657A1 (en) Treatment of middle east respiratory syndrome coronavirus
US20200222511A1 (en) Treatment of merkel cell polyomavirus infection
ES2786025T3 (es) Productos conjugados de proteína-polímero
CN114712490A (zh) 包含重组酸性α-葡糖苷酶的配制品
KR20140130705A (ko) 체강액 저류 억제제
NZ790135A (en) Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof
WO2020018785A1 (en) Methods of treating angioedema